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Abstract
Transplantation of encapsulated living cells is a promising approach for the treatment of a wide variety of diseases. Large-scale
application of the technique, however, is hampered by insufﬁcient biocompatibility of the capsules. In the present study, we have
implemented new as well as previously reported technologies to test biocompatibility issues of immunoisolating microcapsules on
the long term (i.e. 2 years) instead of usually reported short time periods. When transplanted empty, the capsules proved to be highly
biocompatible not only for short periods (i.e. 1 month) but also on the long term as evidenced by the absence of any signiﬁcant
biological response up to 2 years after implantation in rats. The immunoprotective properties of the capsules were conﬁrmed by
prolonged survival of encapsulated islet allografts up to 200 days. The surface of the applied capsule was analyzed and provides new
insight in the chemical structure of true biocompatible and immunoprotective capsules applicable for transplantation of
encapsulated islets in type I diabetes.
r 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The recent advances in clinical islet transplantation [1]
have increased the interest in transplantation of an
endogenous insulin source for control of the diabetic
blood sugar. A major obstacle to overcome the large-
scale application is the requirement to apply effective
immunosuppression, which is associated with serious
side effects, especially when applied for a life-long period.
Immunoisolation by microencapsulation does not re-
quire the use of immunosuppression and has therefore
the potential to be developed into a widely applicable
therapy for patients with insulin dependent diabetes.
A commonly used procedure for immunoprotection is
microencapsulation of tissues in alginate-based capsules
as originally described by Lim and Sun [2]. During
recent years, important advances have been made with
this technology. Human trials have been started and
showed temporary but pertinent survival of human
microencapsulated tissue after allotransplantation of
encapsulated parathyroid cells [3] and islets [4]. Also,
microencapsulation has been shown to allow for
prolonged survival of xenotransplanted islet grafts in
both chemically induced and autoimmune diabetic
rodents [5], dogs [4], and monkeys [6]. Although this
illustrates the principle applicability of the alginate-
encapsulation technique, a fundamental barrier has to
be overcome since graft survival varies considerably
from several days to months [7]. This variation in
success rate is usually attributed to differences in the
biological responses (i.e. biocompatibility) against the
applied capsules. In order to improve the capsule
properties, many groups have introduced their own
technical modiﬁcations. As a consequence there are
many different procedures with speciﬁc chemical char-
acteristics which, regretfully, are never documented.
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In the foregoing years we have concentrated on the
identiﬁcation and deletion of factors inducing biological
responses against encapsulated islets. Alginates are
composed of mannuronic acid (M) and guluronic acid
(G) and can be contaminated with inﬂammatory
substances. We found that the biological response
against capsules can be reduced by applying alginates
with a G-content of 40–45% instead of more than 50%
and by introducing alginates with a high purity degree
[5,8–11]. Also, an inadequate mechanical integrity of the
capsules [9,12] can cause immunological reactions in the
recipient. Finally, we found that grafts can fail as the
consequence of incomplete encapsulation of islets [13,14].
In the present study, we changed the capsule
production process by applying modiﬁcations which
have previously shown to inﬂuence the biological
response against capsule grafts [5,8–12]. Empty capsules
produced according to our modiﬁed procedure were
implanted in the peritoneal cavity and retrieved after
varying time intervals for evaluation of the biological
response against the capsules. Next, syngeneic and
allogeneic rat islets were encapsulated and transplanted
in diabetic rats in order to assess the immunoprotective
properties of the capsules. Finally, we analyzed and
present the chemical structure of the immunoprotective
capsule, which remained free of any biological response
up to 2 years after implantation in rats.
2. Materials and methods
2.1. Design of the study
Only highly puriﬁed alginates were applied in order to
exclude that contaminating components were the cause
of an inﬂammatory response. Capsules were prepared of
alginates with an intermediate guluronic acid (G)
content (40%G) in order to prevent biological responses
associated with a high G-content. High viscosity alginate
solutions were applied to produce capsules with an
adequate mechanical integrity. The capsules were
inspected before and after implantation in order to
conﬁrm that the majority of the capsules was intact.
Batches of empty alginate-PLL capsules were divided
into six portions. Five samples were implanted in the
peritoneal cavity, i.e. the usual transplantation site for
an encapsulated islet graft, of ﬁve AO-rats. The sixth
sample was stored for analyses of the chemical structure
of the capsules. At 1, 3, 6, 12, or 24 months after
implantation, one of the ﬁve implanted rats was killed
and subjected to peritoneal lavage. We used ﬁve series of
ﬁve rats for this experiment. Recipients of capsules
prepared from unpuriﬁed alginates served as controls.
Streptozotocin diabetic AO-rats served as recipients
of capsules containing either AO-(isografts) or Lewis-
islets (allografts). Non-encapsulated allografts served as
controls. At 4 weeks after the implantation of successful
encapsulated islet allografts the rats were provided with
cardiac catheters implanted via the right jugular vein for
blood sampling in unanaesthetized and freely moving
rats [15,16]. Subsequently, the glucose tolerance of
encapsulated islet allografts was tested by a meal test.
Normal AO-rats served as controls. One or two weeks
after the reoccurrence of hyperglycemia (i.e. blood
glucose levels >8.4mmol/l), microcapsules were re-
trieved from the diabetic recipients by peritoneal lavage.
Empty or islet containing capsules retrieved by
peritoneal lavage were always processed for histological
examination of the degree of overgrowth of the graft
(i.e. a measure for the biological response against the
capsules [5,8,9,12] ).
2.2. Islet isolation and graft recipients
Male inbred Albino Oxford (AO/G) rats were
obtained from the Central Animal Laboratory of
Groningen. AO/G-rats weighing 300–350 g served as
donors. AO/G-rats weighing 290–320 g were used as
recipients of islet grafts. Diabetes was induced in these
rats by injection of 75–90mg/kg of Streptozotocin
(Zanosar, Upjohn Co., Kalamazoo, MI) via the tail
vein.
Islets were isolated as previously described [17].
Brieﬂy, after surgical from the abdomen, the pancreas
was chopped, digested using a two stage incubation of
20min at 371C with successively 1.0 and 0.7mg/ml
collagenase (Sigma type XI, Sigma, St. Louis, MO,
USA). Islets were separated from exocrine tissue using a
discontinuous dextran gradient [18] and further puriﬁed
by handpicking. The total islet volume obtained by the
isolation procedure was determined by measuring the
diameters of islets in a 4% aliquot of the islet
suspension. In each transplant experiment we collected
3500–4200 islets which corresponds to 10–15 ml of islet
tissue which is approximately equal to the endocrine
volume of one normal pancreas.
2.3. Alginates
Sodium alginate was obtained from Kelco Interna-
tional, London, UK. Puriﬁcation of alginate was
performed as described in detail by our group elsewhere
[8]. All identiﬁed factors inﬂuencing biological responses
were tested in the present study [5,8–14]. The composi-
tion of the alginate was studied after puriﬁcation by
nuclear magnetic resonance analysis [8]. Only alginates
with a G-content between 40% and 45% were applied
[11]. Selected alginates were dissolved at 41C in Krebs–
Ringer–Hepes (KRH) with an appropriate osmolarity to
a solution with a viscosity of 4 cps. This viscosity is
necessary for the production of spherical droplets
without any tails or other imperfections associated with
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bioincompatibility. The viscosity of an alginate solution
is determined by the concentration of alginate but
different alginates have different viscosities. This implies
for the intermediate-G (i.e. low viscosity) solution a
concentration of 3% to obtain a viscosity of 4 cps. The
solutions were sterilized by 0.2 mm ﬁltration.
2.4. Encapsulation
Capsules were produced according to a three-step
procedure. First, we produced rigid Ca-alginate beads,
by converting an alginate solution into droplets using an
air-driven droplet generator as previously described [19].
The droplets were collected in a Ca-rich solution to
gelify into rigid Ca-beads. Secondly, the Ca-beads were
subjected to a procedure to form a semipermeable PLL-
membrane. Finally, to cover incompletely bound PLL,
the alginate-PLL beads were coated to form a so-called
second Ca-alginate layer [20]. Capsules had a diameter
of 600–700 mm. All procedures were performed under
sterile conditions.
For producing islet-containing capsules islets were
mixed with alginate in a ratio of 2000/ml alginate. This
ratio is required to prevent protrusion of islets [21]. The
adequacy of encapsulation was controlled before graft-
ing by applying our lectin-binding assay [13,14] for
identiﬁcation of protruding and incompletely encapsu-
lated islets. The percentage of inadequate capsules was
always less than 3% of the total amount of capsules.
Capsules were injected into the peritoneal cavity.
Upon peritoneal lavage, microcapsules were either freely
ﬂoating and non-adherent, or adherent to the surface of
abdominal organs. First, non-adherent microcapsules
were retrieved by peritoneal lavage, and brought into a
syringe with appropriate measures for quantiﬁcation of
the retrieval rate [12]. Subsequently, the microcapsules
adherent to the surface of abdominal organs, were
excised and processed for histology.
All surgical procedures were performed under ha-
lothane anesthesia.
2.5. X-ray photoelectron spectroscopy (XPS)
XPS is a technology in which X-ray is applied onto
the surface of an object of interest. This X-ray induces
the release of kinetic energy from the surface which is
collected by a spectroscope. The kinetic energy can be
analyzed and is characteristic for the elements present in
the surface of the object.
For XPS analyses in the present experiments, Ca-
beads (i.e. alginate-droplets geliﬁed in a Ca-rich solu-
tion) and capsules were three times washed with
ultrapure water and gradually lyophilized (Leybold
Herecuis, Combitron CMI). Since the spectroscope only
identiﬁes elements at the surface of the capsules, it is a
prerequisite that the membranes of the capsules are
intact and not broken. Therefore, before applying XPS,
we conﬁrmed the integrity of the surfaces and mem-
branes both at low magniﬁcation (i.e. by light micro-
scopy) and at high magniﬁcation (i.e. by scanning
electron microscopy).
Samples of lyophilized beads or capsules with intact
capsule membranes were ﬁxed on a sample holder. The
sample holder was inserted into the chamber of a X-ray
photoelectron spectrometer (Surface Science Instru-
ments, S-probe, Mountain View, CA). An aluminum
anode was used for generation of X-rays (10 kV, 22mA)
at a spot size of 250 1000 mm. During the measure-
ments, the pressure in the spectrometer was approxi-
mately 107 Pa. First, scans were collected over the
binding energy range of 1–1100 eV at low resolution
(150 eV pass energy). Next, we recorded at high
resolution (50 eV pass energy) C1s, N1s, and O1s peaks
over a 20 eV binding energy range. Experiments with
beads and capsules were repeated four times to exclude
variations between different encapsulation sessions.
2.6. Microscopy
The biological response against capsules was assessed
by quantifying the number of capsules overgrown by
macrophages and ﬁbroblasts [5,9]. Therefore, samples of
adherent capsules recovered by excision and non-
adherent capsules were ﬁxed in pre-cooled 2% para-
formaldehyde, buffered with 0.05m phosphate in saline
(pH 7.4), and processed for glycol methacrylate (GMA)
embedding [22]. Sections were prepared at 2 mm and
stained with Romanovsky–Giemsa stain and applied for
detecting imperfections in the capsule membrane and for
determining the number of capsules with and without
overgrowth. The degree of capsular overgrowth was
quantiﬁed by expressing the number of recovered
capsules with overgrowth as the percentage of the total
number of recovered capsules for each individual animal
[5,8,9,12].
2.7. Glucose tolerance testing
The meal tests were carried out by offering the animal
2 g rat chow (containing 53% carbohydrates, 20%
protein, 5% fat and 22% other constituents (minerals,
cellulose, water), mixed with 2ml water. The animals
had been habituated to consume the meal within 5min.
Blood samples were taken at 10min and immediately
before the start of the tests, and at 1, 3, 5, 7, 10, 15, 20,
25, 30, 45, 60, 75, 90, 105, and 120min after the start of
the tests. Blood lost during sampling was replaced by
transfusing blood from normal donor rats after every
blood sample. Glucose concentrations were determined
in whole blood by a ferricyanide method with a
Technicon autoanalyzer.
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2.8. Statistical analysis
Results are expressed as mean7SEM. Statistical
comparisons were made with the Mann–Whitney U-
test. A P-value o0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Biological response against empty capsules
The vast majority of empty alginate-PLL capsules was
freely ﬂoating in the peritoneal cavity without adhesion
to the abdominal organs (Fig. 1A). The free capsules
could readily be ﬂushed out of the peritoneal cavity,
resulting in an explantation of 80–100% up to 2 years
postimplant (Table 1). Of the recovered capsules only a
portion of not more than 10% of the capsules contained
some macrophages and ﬁbroblasts. This small percen-
tage of overgrowth was caused by imperfections on the
capsule surface since we recurrently observed that some
capsules contained defects which were surrounded by
inﬂammatory tissue or ﬁbroblasts.
Empty capsules prepared of unpuriﬁed alginate were
all overgrown by ﬁbrotic tissue within 1 month
postimplant. The capsules were found to be adherent
to omentum tissue (Fig. 1B), liver, and guts.
3.2. The surface chemical composition of biocompatible
capsules
Capsules are usually considered to be composed of a
Ca-bead covered by a two-layer membrane of alginate-
PLL for immunoprotection, and of Ca-alginate to
prevent biological reactions associated with non-bound
PLL [5,23]. This is an assumption which is based on the
theoretical three-step procedure applied for producing
capsules and not on data from chemical evaluations of
true capsules. To get a full insight on the chemical
structure of biocompatible capsules, we evaluated the
structure of the surface by applying X-ray photoelectron
spectroscopy (XPS). To get a full insight in the structure
of the elemental capsule-structure we analyzed both the
Ca-beads and the membrane.
As shown in Table 2, the surface of Ca-beads was
composed of the elements carbon and oxygen, which
originate from the alginate. Also, we observed the
elements Ca and Cl which derive from the CaCl2 applied
for crosslinking of the alginate molecules.
The membrane was as expected different in composi-
tion. We found nitrogen which derives from the PLL
bound by alginate. Surprisingly, we found no calcium in
the surface of the membrane. Instead, we found some
sodium which is probably bound by carboxyl groups
present in alginate.
Fig. 1. Explanted alginate-PLL capsules 1 year after implantation in
the peritoneal cavity of rats. (A) Capsules were produced according to
the procedure in which physical, chemical, and immunological factors
inﬂuencing the biological response against capsules were successfully
controlled (original magniﬁcation  70). Note that the capsule is free
of any obvious cell-adhesion. (B) Histological section of capsules were
produced from unpuriﬁed, crude alginate. All capsules are adherent to
omental tissue (GMA-embedded histological section, Syrius Red
staining, original magniﬁcation  50).
Table 1
Recovery rates of capsules after lavage and percentage of empty
alginate-PLL capsules with overgrowth at 1, 3, 6, 12 and 24 months








1 5 94.673.0 6.071.5
3 5 87.477.5 7.972.0
6 5 91.673.5 3.472.0
12 5 94.674.5 5.272.1
24a 2 85,90 9,4
aThree out of ﬁve rats died because of old age before the 24 months
time point. The results of the remaining two animals are given
individually.
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3.3. Adequacy of immunoprotection
Transplantation of free, non-encapsulated islets allo-
grafts in diabetic AO-rats induced normoglycemia for
not more than 2 days after which the islets were fully
rejected. In contrast, diabetic recipients of encapsulated
islet allografts became normoglycemic within 5 days
postimplant and remained normoglycemic for 42 till
more than 200 days (Fig. 2).
During meal testing, the blood glucose levels of
encapsulated islet allografts were somewhat elevated
when compared to normal controls (Fig. 3). However,
blood glucose levels never exceeded 8.0mmol/l which
illustrates the adequacy of blood glucose control by the
encapsulated grafts.
Isografts showed similar survival times as allografts
(Table 3) which suggests that eventual failure of
encapsulated islet allografts was not caused by rejection.
This argumentation was further substantiated by our
observation that we found no inﬂammatory cells
indicating an ongoing process of rejection in the
transplantation site. Capsules containing islet isografts
or allografts were freely ﬂoating in the peritoneal cavity
and only a small portion of imperfect capsules of less
than 10% was overgrown by macrophages and ﬁbrotic
tissue. Some capsules, however, contained some pre-
cipitates which were retained by the capsule membrane
(Fig. 4A) and in our histological studies we found many
islets containing central necrosis (i.e. dead cells in the
center of the islets) (Fig. 4B). This indicates that failure
is caused by islet-cell death within the capsule [12],
which results from either islet toxicity because of
deposition of metabolic waste, or from nutrient deﬁ-
ciency.
4. Discussion
Up to now the success rates of transplantation of
microencapsulated islets were low [5,24–27]. This is
Table 2
Elemental surface composition of Ca-beads (n ¼ 4) and alginate-PLL capsules (n ¼ 4) before implantation and an analysis of pure PLL
(representative sample is shown)
C (%) N (%) O (%) Ca (%) Na (%) Cl (%) Others (%)a
Ca-beads 55.470.8 0 33.371.1 5.470.4 0 3.770.6 2.2
Alginate-PLL capsules 58.671.9 6.270.5 31.470.8 0 2.770.4 0 1.1
PLL 67.2 10.7 17.9 0 0 4.2 0
a such as S and Si.
Fig. 2. Non-fasting blood glucose concentrations in streptozotocin
diabetic AO-rats after implantation of microencapsulated allografts
(closed symbols, n ¼ 7) or non-encapsulated, free islet allografts (open
symbols, n ¼ 6). All the recipients of non-encapsulated, free allogenic
islets became normoglycemic for not more than 2 days. The number of
cured, normoglycemic recipients of microencapsulated allografts at the
different time points is shown in parentheses. Values represent
mean7SEM.
Fig. 3. Blood glucose levels after spontaneous ingestion of a meal
(n ¼ 6) in AO-recipients of microencapsulated allografts (closed
symbols) and in normal controls (open symbols). Values represent
mean7SEM.
Table 3
Mean graft survival, recovery rates and percentage of capsules with
overgrowth after implantation of microencapsulated rat islet iso- and
allografts. Values represent mean7SEM. Note that the survival times











Isograft 5 98.4711.5 83.279.1 8.972.4
Allograft 7 102.679.7 88.574.7 7.473.5
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mainly caused by insufﬁcient biocompatibility of the
applied capsule materials [5,28–30] which induced a
non-speciﬁc foreign body reaction against not only a
small portion but against the whole capsule graft with
ﬁbrosis of the capsules and necrosis of the islets as a
consequence. In the present study, we show for the ﬁrst
time that a procedure in which pertinent factors
inducing tissue responses against the capsules are
deleted, can create a capsule graft which does not elicit
any signiﬁcant biological response up to 2 years of
implantation in the rat, i.e. the life-span of a rat.
Unfortunately, the application of biocompatible
capsules in islet transplantation did not bring about
permanent survival of the graft since graft survival was
limited to periods of 42 till 200 days. There are several
lines of evidence supporting that this limited duration of
graft survival was not caused by insufﬁcient biocompat-
ibility or inadequate immunoprotection. First, only a
portion of less than 10% of the capsules was affected by
ﬁbrotic overgrowth, the loss of which has been shown
not to interfere with graft function [8]. Second, we found
that isografts survived for similar if not identical time
periods as allografts which illustrates the adequacy of
immunoprotection. Instead, we found clear indications
that graft failure was associated with insufﬁcient supply
of nutrients and deposition of metabolic waste in the
capsules as evidenced by our observation of central
necrosis in the islets and depositions of metabolic waste
in the capsules.
Our study differs from previous work in several ways.
First, we have documented in the present transplanta-
tion series in contrast to our previous series all available
factors inﬂuencing biocompatibility of the capsules [2].
As a consequence the survival times of encapsulated islet
grafts was improved with a mean of several months
when compared to previous studies [8]. This documen-
tation of factors inﬂuencing biocompatibility is perti-
nent for comparing studies between different groups in
the ﬁeld since many have introduced their own technical
modiﬁcations without further documentation of the
consequences of these changes for the properties of the
capsules. We have often observed that these kind of
emperic changes have a drawback on essential proper-
ties of the capsules. For example, in alginate-PLL
capsules the application of high-G alginates to improve
the mechanical characteristics of capsules holds the
pitfall of a drawback in biocompatibility since high-G
alginate interact inadequately with the inﬂammatory
poly-l-lysine [14]. Another difference between previous
and the present study is that we have introduced a new
technique to document the chemical composition of the
capsules. This will contribute to a better understanding
of the chemical factors determining success and failure
of the capsule graft.
The present study gives new insight in the structure of
the membrane of alginate-PLL capsules. Up to now
(Fig. 5A), the capsule was assumed to be composed of a
core of Ca-alginate which is enveloped by a membrane
composed of two layers, i.e. an inner layer of alginate-
PLL and an outer layer of Ca-alginate [2,23,31]. The
data, which have lead to this model, were almost
exclusively obtained by studying the chemical interac-
tions of PLL with solved, non-Ca bound and often
individual components of alginate (i.e. guluronic (G)-
acid and mannuronic (M)-acid monomers) and not by
studying the chemical structure of the capsules as such.
In the present study on true capsules, we never observed
Ca2+ in the membrane of the capsules, which has the
following implications for the assumed structure of the
capsules. First, the alginate-PLL layer is not composed
of the combination of alginate-PLL and alginate-Ca2+
but of the alginate-PLL only. The absence of Ca2+ also
implies that the outer Ca-alginate layer does not exist
and, consequently, that the membrane is not composed
of two but of one layer only. Finally, we found sodium
in the membrane, which is bound by carboxyl groups on
consecutive blocks of G- and M-molecules, which
Fig. 4. Causes of failure of microencapsulated islet grafts. (A) An islet-
containing capsule retrieved 180 days postimplant. Note the hazy layer
underneath the membrane which is a deposition of metabolic waste
material that cannot pass freely through the capsule membrane
(original magniﬁcation  70). (B) An islet-containing capsule retrieved
100 days postimplant. The arrow indicates the necrotic center of the
islet (GMA-embedded histological section, original magniﬁcation
 150).
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remain unbound between the complexes of PLL and
mixed sequences of G and M. Fig. 5B shows the actual
structure of alginate-PLL capsules.
The present study shows that capsules prepared of
alginates are biocompatible and stable in vivo up to 2
years after implantation and, thereby, deletes the major
obstacle in clinical applicability of microencapsulated
islets. The capsules do not interfere with islet-function
and effectively protects the islets against rejection as
illustrated by the prolonged survival of the graft. In our
attempts to further improve the survival of the grafts we
focus on two approaches. First, we are determining the
optimal permeability of the capsules in order to create a
porosity, which allow for fast exchange of metabolic
waste materials and essential nutrients while compo-
nents of the immune system, which can interfere with
islet function, are not able to pass the membrane. The
other approach is to ﬁnd a transplantation site which is
better vascularized than the unmodiﬁed peritoneal
cavity warranting adequate exchange of nutrients,
metabolic waste, glucose and insulin. Such a site should
also hold the advantage of retrievability of the graft in
case encapsulated grafts will require repeated replace-
ments. These studies are pertinent for the design of
strategies applicable for clinical islet transplantation.
References
[1] Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E,
Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation
in seven patients with type 1 diabetes mellitus using a
glucocorticoid-free immunosuppressive regimen. N Engl J Med
2000;343:230–8.
[2] Lim F, Sun AM. Microencapsulated islets as bioartiﬁcial
endocrine pancreas. Science 1980;210:908–10.
[3] Hasse C, Kl .ock G, Schlosser A, Zimmermann U, Rothmund M.
Parathyroid allotransplantation without immunosuppression.
Lancet 1997;350:1296–7.
[4] Soon-Shiong P, Feldman E, Nelson R, Komtebedde J, Smidsrod
O, Skj(ak-Bræk G, Espevik T, Heintz R, Lee M. Successful
Fig. 5. Schematic presentation of the composition of the alginate-PLL membranes. (A) The two-layer model as originally proposed by Thu et al.
[23,32]. The inner layer of alginate-PLL is considered to be formed by two types of interactions. The ﬁrst type is that of interactions between PLL and
mixed sequences of guluronic acid (G) and mannuronic acid (M) in the alginate molecules. This interaction reduces the permeability of the capsules
by inducing the formation of complexes at the capsule surface of a-helical PLL surrounded by superhelically orientated polysaccharide molecules
[33,34]. The other interaction is that between Ca2+ and alginate which is already formed in the gelation step in 100mm CaCl2 [35]. In this step, Ca
2+
has connected alginate molecules by binding consecutive G-blocks located on each of both molecules in a highly cooperative manner [35]. The outer
layer, the layer of Ca-alginate, is also composed of connections between Ca2+ and alginate B. The actual membrane structure as follows from our
XPS analysis. We found no Ca2+ in the membrane but only alginate, PLL and Na+ (for further explanation see Section 4).
P. de Vos et al. / Biomaterials 24 (2003) 305–312 311
reversal of spontaneous diabetes in dogs by intraperitoneal
microencapsulated islets. Transplantation 1992;54(5):769–74.
[5] Fritschy WM, De Vos P, Groen H, Klatter FA, Pasma A, Wolters
GH, Van Schilfgaarde R. The capsular overgrowth on micro-
encapsulated pancreatic islet grafts in streptozotocin and auto-
immune diabetic rats. Transplant Int 1994;7:264–71.
[6] Sun YL, Ma XJ, Zhou DB, Vacek I, Sun AM. Normalization of
diabetes in spontaneously diabetic cynomologus monkeys by
xenografts of microencapsulated porcine islets without immuno-
suppression. J Clin Invest 1996;98:1417–22.
[7] O’Shea GM, Goosen MFA, Sun AM. Prolonged survival of
transplanted islets of Langerhans encapsulated in a biocompatible
membrane. Biochim Biophys Acta 1984;804:133–6.
[8] De Vos P, De Haan BJ, Wolters GHJ, Strubbe JH, Van
Schilfgaarde R. Improved biocompatibility but limited graft
survival after puriﬁcation of alginate for microencapsulation of
pancreatic islets. Diabetologia 1997;40:262–70.
[9] De Vos P, Wolters GH, Fritschy WM, Van Schilfgaarde R.
Obstacles in the application of microencapsulation in islet
transplantation. Int J Artif Org 1993;16:205–12.
[10] De Vos P, Wolters GHJ, Van Schilfgaarde R. Possible relation-
ship between ﬁbrotic overgrowth of alginate- polylysine-alginate
microencapsulated pancreatic islets and the microcapsule integ-
rity. Transplant Proc 1994;26:782–3.
[11] De Vos P, De Haan B, Van Schilfgaarde R. Effect of the alginate
composition on the biocompatibility of alginate-polylysine
microcapsules. Biomaterials 1997;18:273–8.
[12] De Vos P, van Straaten JF, Nieuwenhuizen AG, de Groot M,
Ploeg RJ, De Haan BJ, Van Schilfgaarde R. Why do micro-
encapsulated islet grafts fail in the absence of ﬁbrotic overgrowth?
Diabetes 1999;48:1381–8.
[13] De Vos P, De Haan BJ, Pater J, Van Schilfgaarde R. Association
between capsule diameter, adequacy of encapsulation, and
survival of microencapsulated rat islet allografts. Transplantation
1996;62:893–9.
[14] De Vos P, De Haan BJ, Wolters GHJ, Van Schilfgaarde R.
Factors inﬂuencing the adequacy of microencapsulation of rat
pancreatic islets. Transplantation 1996;62:888–93.
[15] Steffens AB. A method for frequent sampling of blood and
continuous infusion of ﬂuids in the rat without disturbing the
animal. Physiol Behav 1969;4:833–6.
[16] De Vos P, Vegter D, De Haan BJ, Strubbe JH, Bruggink JE, Van
Schilfgaarde R. Kinetics of intraperitoneally infused insulin in
rats: functional implications for the bioartiﬁcial pancreas.
Diabetes 1996;45:1102–7.
[17] Wolters GH, van Suylichem PT, Van Deijnen JH, Van
Schilfgaarde R. Factors inﬂuencing the isolation process of islets
of Langerhans. Horm Metab Res Suppl 1990;25:20–6.
[18] van Suylichem PT, Wolters GH, Van Schilfgaarde R. The efﬁcacy
of density gradients for islet puriﬁcation: a comparison of seven
density gradients. Transplant Int 1990;3:156–61.
[19] Wolters GHJ, Fritschy WM, Gerrits D, Van Schilfgaarde R. A
versatile alginate droplet generator applicable for microencapsu-
lation of pancreatic islets. J Appl Biomater 1992;3:281–6.
[20] Fritschy WM, Wolters GH, Van Schilfgaarde R. Effect of
alginate-polylysine-alginate microencapsulation on in vitro in-
sulin release from rat pancreatic islets. Diabetes 1991;40:37–43.
[21] De Vos P, De Haan BJ, Van Schilfgaarde R. Upscaling the
production of encapsulated islets. Biomaterials 1997;18:1085–90.
[22] Fritschy WM, Gerrits PO, Wolters GH, Pasma A, Van
Schilfgaarde R. Glycol methacrylate embedding of alginate-
polylysine microencapsulated pancreatic islets. Biotech Histo-
chem 1995;70:188–93.
[23] Thu B, Bruheim P, Espevik T, Smidrod O, Soon-Shiong P,
Skjak-Braek G. Alginate polycation microcapsules. I. Inter-
action between alginate and polycation. Biomaterials 1996;17:
1031–40.
[24] Sun AM. Advantages of microencapsulation as an immunopro-
tection method in the transplantation of pancreatic islets. Ann
Transplant 1997;2:55–62.
[25] Bodziony J. Bioartiﬁcial endocrine pancreas: foreign-body reac-
tion and effectiveness of diffusional transport of insulin and
oxygen after long-term implantation of hollow ﬁbers into rats.
Res Exp Med Berl 1992;192:305–16.
[26] Clayton HA, London NJM, Colloby PS, Bell PRF, James RFL.
A study of the effect of capsules composition on the viability of
cultured alginate/poly-l-lysine-encapsulated rat islets. Diabetes
Res 1990;14:127–32.
[27] Klock G, Pfeffermann A, Ryser C, Grohn P, Kuttler B, Hahn HJ,
Zimmermann U. Biocompatibility of mannuronic acid-rich
alginates. Biomaterials 1997;18:707–13.
[28] Soon-Shiong P, Otterlei M, Skj(ak-Br!ck G, Smidsrod O, Heintz R,
Lanza RP, Espevik T. An immunological basis for the ﬁbrotic
reaction to implanted microcapsules. Transplant Proc 1991;23:
758–9.
[29] Klock G, Frank H, Houben R, Zekorn T, Horcher A, Siebers U,
Wohrle M, Federlin K, Zimmermann U. Production of puriﬁed
alginates suitable for use in immunoisolated transplantation. Appl
Microbiol Biotechnol 1994;40:638–43.
[30] Gotfredsen CF, Stewart MG, O’Shea GM, Vose JR, Horn T,
Moody AJ. The fate of transplanted encapsulated islets in
spontaneously diabetic BB\WOR rats. Diabetes Res 1990;15:
157–63.
[31] Dupuy B, Arien A, Perrot Minnot A. FI-IR of membranes made
with alginate-polylysine complexes. Variations with mannuronic
or guluronic content of the polysaccharides. Art Cell Blood Subs
Imm Biotech 1994;22:71–82.
[32] Thu B, Bruheim P, Espevik T, Smidrod O, Soon-Shiong P, Skjak-
Break G. Alginate polycation microcapsules II. Some functional
properties. Biomaterials 1996;17:1069–79.
[33] Bystricky S, Malovikova A, Sticzay T. Interaction of acid
polysaccharides with polylysine enantiomers, conformation probe
in solution. Carbohydr Polym 1991;15:299–308.
[34] Bystricky S, Malovikova A, Sticzay T. Interaction of alginate and
pectins with cationic polypeptides. Carbohydr Res 1990;13:
283–94.
[35] Smidsrod O, Skjak-Break G. Alginate as immobilization matrix
for cells. Trends Biotechnol 1990;8:71–8.
P. de Vos et al. / Biomaterials 24 (2003) 305–312312
